Original ArticlesLarge-Scale Screening and Molecular Characterization of EML4-ALK Fusion Variants in Archival Non–Small-Cell Lung Cancer Tumor Specimens Using Quantitative Reverse Transcription Polymerase Chain Reaction Assays
Key Words
Cited by (0)
In summary, we here report the detection of 200 EML4-ALK fusion variants in 7344 North American NSCLC patients (2.7%) using variant-specific, quantitative RT-PCR assays. ALK expression level varied significantly among different EML4-ALK-positive variants and individual NSCLC tumors. EML4-ALK-positive tumors had a significantly lower TS RNA level compared with that of EML4-ALK-negative lung adenocarcinomas, a potential molecular basis for clinical response of ALK-positive tumors to pemetrexed. Further evaluation of these variant-specific, quantitative RT-PCR assays as an adjuvant to the standard FISH assay is warranted to better understand biologic variability and response patterns to ALK inhibitors. It remains to be determined how to integrate these quantitative RT-PCR assays into the cost-effective diagnostic algorithm for ALK+ tumors and whether patient tumors detected by different methods are equally sensitive to ALK inhibitors.
Presented in part at the 2010–2012 Annual Meetings of the American Society of Clinical Oncology, Chicago, IL (Dannenberg et al., ASCO 2010: Abs #10535; Li et al., ASCO 2011: Abs #10520; and Li et al., ASCO 2012: Abs #7594; Gandara et al., ASCO 2012: Abs #7582).
Disclosure: TL is supported by UL1 RR024146 from the National Center for Research Resources, UC Davis Comprehensive Cancer Center Developmental Award (National Institutes of Health/National Cancer Institute P30CA093373), and the Hope Foundation (Southwest Oncology Group Young Investigator Award). MKH, CS, EH, JH, GZ, and SHA are employees of RGI. KDD is a former employee of RGI. DRG serves as a consultant for RGI. The remaining authors declare no conflict of interest.